Literature DB >> 2438510

Calcium antagonist properties of diclofurime isomers. II. Molecular aspects: allosteric interactions with dihydropyridine recognition sites.

A K Mir, M Spedding.   

Abstract

Trans-diclofurime has been shown to be a very potent class II calcium antagonist (see preceding report), and we have examined its molecular interactions with the different receptor sites at the Ca2+ channel. Trans-diclofurime did not affect [3H]nitrendipine binding to rat cortical membranes at 37 degrees C and showed weak inhibitory effects at 25 degrees C, whereas at 0 degrees C 80% of the binding was inhibited noncompetitively (IC50, 13 nM); cis-diclofurime was 22-fold less potent. Trans-diclofurime, like diltiazem, blocked the inhibitory effects of verapamil on [3H]nitrendipine binding. Trans-diclofurime is a potent displacer of [3H]diltiazem binding (IC50, 15 nM; IC50 for diltiazem, 55 nM); the diclofurime isomers showed high stereoselectivity, with high Hill coefficients (0.85-1.0). In contrast, the stereoselectivity of the isomers was lower as inhibitors of [3H]verapamil binding, as were the Hill coefficients (0.55-0.65). It is proposed that the functional potency of the diclofurime isomers as calcium antagonists can be explained on the basis of their relative affinities for the diltiazem site and that this site is coupled to the dihydropyridine site in a positive heterotropic allosteric manner. A model for the interaction of group II calcium antagonists with the Ca2+ channel is proposed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438510     DOI: 10.1097/00005344-198704000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Interaction of palmitoyl carnitine with calcium antagonists in myocytes.

Authors:  L Patmore; G P Duncan; M Spedding
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

2.  Selective antagonism of calcium channel activators by fluspirilene.

Authors:  B A Kenny; S Fraser; A T Kilpatrick; M Spedding
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

3.  Pharmacophore modelling of structurally unusual diltiazem mimics at L-type calcium channels.

Authors:  K J Schleifer; E Tot
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

4.  [3H]HOE166 defines a novel calcium antagonist drug receptor--distinct from the 1,4 dihydropyridine binding domain.

Authors:  A Grassegger; J Striessnig; M Weiler; H G Knaus; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

5.  Very high affinity interaction of DPI 201-106 and BDF 8784 enantiomers with the phenylalkylamine-sensitive Ca2(+)-channel in Drosophila head membranes.

Authors:  H Glossmann; C Zech; J Striessnig; R Staudinger; L Hall; R Greenberg; B I Armah
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

6.  Effect of propionyl-L-carnitine on L-type calcium channels in human heart sarcolemma.

Authors:  M Bevilacqua; T Vago; G Norbiato
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

7.  Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166.

Authors:  J Striessnig; E Meusburger; M Grabner; H G Knaus; H Glossmann; J Kaiser; B Schölkens; R Becker; W Linz; R Henning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-03       Impact factor: 3.000

8.  Identification of a novel calcium antagonist binding site in rat brain by SR 33557.

Authors:  B A Kenny; S Fraser; M Spedding
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

9.  Comparison of the cardiovascular effects of trans-diclofurime with different types of calcium antagonists in conscious spontaneously hypertensive rats.

Authors:  M A Petty; A K Mir
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.